Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Hamilton Thorne Announces New CASA Products at 2014 American Society for Reproductive Medicine Meeting

T.HTL, BIOGY

BEVERLY, MA and TORONTO, ON--(Marketwired - Oct 21, 2014) - Hamilton Thorne Ltd. (TSX VENTURE: HTL), a leading provider of precision laser devices and advanced image analysis systems for the fertility, stem cell and developmental biology research markets, today announced a number of product releases at the annual American Society for Reproductive Medicine meeting being held in Honolulu, Hawaii from October 18 to October 22, 2014.

New Product Announcements

  • Accu-beads+ Three Level Quality Control -- (3 M/ml, 18 M/ml, 35 M/ml) -- Similar in size to human sperm, the Accu-beads+ quality control product confirms accurate counting procedures used for clinical automated semen analysis on our IVOS and CEROS systems. Hamilton Thorne has added a third low-level concentration of 3 M/ml to complement the 18 M/ml and 35 M/ml concentrations already available. This lower concentration offers greater procedural confidence when accurate assessment of low sperm numbers is required by WHO.

  • Remote Capture -- Remote Capture is a new option for satellite laboratories allowing capture of sperm motility videos to send for analysis and report creation on an IVOS II or CEROS II analyzer at the central facility. Both patient identification and sample information are saved along with the video. A complete remote capture station includes software, high resolution digital camera and PC, with or without microscope. (Available November 2014)

  • DNA Fragmentation -- As an add-on module to the CASA II motility software, the DNA Fragmentation software permits automated measurement of the "halo" that appears around the sperm head on specially prepared sperm samples. The data obtained from determining the percentage of sperm displaying fragmented DNA may assist clinicians in determining the appropriate next step in the IVF process. (Available December 2014)

Certain products listed above are available for research only purposes in the United States.

In addition to the new products, several enhancements to the CASA II systems are now available, including touchscreen compatibility, Windows 8.1 operating system option, and the ability to save video playback with graphic overlays in industry standard .avi format. 

About Hamilton Thorne Ltd. (www.hamiltonthorne.com)

Hamilton Thorne designs, manufactures and distributes precision laser devices and advanced image analysis systems for the fertility, stem cell and development biology research markets. It provides novel solutions for Life Science that reduce cost, increase productivity, improve results and enable research breakthroughs in fertility, regenerative medicine, and stem cell research markets. Hamilton Thorne's laser products attach to standard inverted microscopes and operate as robotic micro-surgeons, enabling a wide array of scientific applications and IVF procedures. Its imaging systems improve outcomes in human IVF clinics and animal breeding facilities and provide high-end toxicology analyses. 

The Company's growing customer base includes pharmaceutical companies, biotechnology companies, fertility clinics, university research centers, and other commercial and academic research establishments worldwide. Current customers include world-leading research labs such as Harvard, MIT, Yale, McGill, DuPont, Monsanto, Charles River Labs, Jackson Labs, Merck, Novartis, Pfizer, and Oxford and Cambridge.

Neither the Toronto Venture Exchange, nor its regulation services provider (as that term is defined in the policies of the exchange), accepts responsibility for the adequacy or accuracy of this release.

Certain information in this press release may contain forward-looking statements. This information is based on current expectations that are subject to significant risks and uncertainties that are difficult to predict. Actual results might differ materially from results suggested in any forward-looking statements. The Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements unless and until required by securities laws applicable to the Company. Additional information identifying risks and uncertainties is contained in filings by the Company with the Canadian securities regulators, which filings are available at www.sedar.com.

For more information, please contact:

David Wolf
President & CEO
Hamilton Thorne Ltd.
978-921-2050
Email Contact

Michael Bruns
CFO
Hamilton Thorne Ltd.
978-921-2050
Email Contact



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today